Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | CASP1 | P29466 | 1/20 | 0.70 |
| ▸ | CASP7 | P55210 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.63 |
| ▸ | GSK3A | P49840 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.58 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7021740 | 0.98 | KDM4E (0.68) | KDM4EALDH1A1HSD17B10RXFP1MAPT | |
| SCHEMBL1421689 | 0.88 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10RXFP1MAPT | |
| SCHEMBL31243787 | 0.88 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10RXFP1MAPT | |
| SCHEMBL31243786 | 0.88 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10RXFP1MAPT | |
| SCHEMBL28383673 | 0.88 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10RXFP1MAPT | |
| SCHEMBL7018012 | 0.86 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10RXFP1MAPT | |
| SCHEMBL13779328 | 0.86 | KDM4E (0.75) | KDM4EALDH1A1HSD17B10RXFP1MAPT | |
| Hydrochloric Acid SCHEMBL7015693 | 0.85 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10RXFP1MAPT | |
| SCHEMBL6462293 | 0.83 | ADORA1 (0.65) | KDM4EALDH1A1HSD17B10RXFP1MAPT | |
| SCHEMBL28748190 | 0.83 | KDM4E (0.63) | KDM4EALDH1A1HSD17B10RXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182105-A1 | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-18 | — | — | US | claimed |
| US-20050182105-A1 | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-18 | — | — | US | disclosed |
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | ASTELLAS PHARMA INC. (JP) | 2003-12-18 | — | — | US | disclosed |
| EP-1302463-A1 | MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | KCNN3, KCNN2, KCNN1 | KDM4E 369/4885ALDH1A1 3292/4885HSD17B10 3642/4885 |
| US-20050182105-A1 | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function | NR3C2, NR4A3, NR3C1 | KDM4E 1261/4885ALDH1A1 2565/4885HSD17B10 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.